Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

Figure 5

Ranking probabilities of the different comparisons for overall survival (a), progression-free survival (b), objective response rate (c), and disease control rate (d). ATE means atezolizumab; DUR means durvalumab; IPI means ipilimumab; PLA means placebo. All these treatments were added to chemotherapy.

(a)

(b)

(c)

(d)